THADA inhibition in mice protects against type 2 diabetes mellitus by improving pancreatic β-cell function and...

Area of Science:

• Endocrinology
• Molecular Biology
• Metabolic Diseases

Background:

• Impaired insulin secretion is a key feature of type 2 diabetes mellitus (T2DM).
• The THADA gene is implicated in T2DM, but its precise role in glucose regulation is unclear.
• THADA expression is elevated in T2DM islets, suggesting a potential contribution to the disease.

Purpose of the Study:

• To investigate the role of THADA in glucose homeostasis and pancreatic beta-cell function.
• To determine the molecular mechanisms by which THADA affects beta-cell function and survival.
• To evaluate THADA as a potential therapeutic target for T2DM.

Main Methods:

• Analysis of THADA expression in human and mouse T2DM islets.
• Generation and characterization of global and beta-cell-specific Thada-knockout mice.
• Investigation of THADA's effects on endoplasmic reticulum (ER) calcium stores and apoptosis pathways.
• Assessment of THADA deficiency and alnustone treatment in diet- and streptozotocin-induced diabetes models.

Main Results:

• Thada-knockout mice showed improved glycemic control, enhanced beta-cell function, and reduced apoptosis.
• THADA was found to deplete ER calcium stores by inhibiting SERCA2 and promoting RyR2-mediated leakage.
• THADA interacts with DR5, FADD, and caspase-8, exacerbating ER stress-induced apoptosis.
• THADA deficiency protected against diet- and streptozotocin-induced hyperglycemia by preserving beta-cell mass and insulin secretion.
• Alnustone treatment inhibited THADA, ameliorating hyperglycemia in obese mice.

Conclusions:

• THADA plays a detrimental role in T2DM by impairing beta-cell function and promoting apoptosis.
• Targeting THADA, for example with alnustone, offers a promising therapeutic strategy for T2DM.
• Further research into THADA's mechanisms could lead to novel T2DM treatments.